About

CagriSema combines two once-weekly injectable hormones: semaglutide, which mimics a gut signal to reduce appetite and slow digestion, and cagrilintide, which mimics a pancreas hormone that promotes fullness. This dual-action approach targets multiple pathways that regulate hunger and calorie intake. The combination may lead to greater and more sustained weight loss than targeting either pathway alone.